22.05.2014 - The price of Pfizer cannot overcome the resistance

The stock price of pharmaceutical company Pfizer continues to consolidate below the strong level 30.00 dollars per share. It is worth noting that in the case of price fixing below this level, as well as the strong resistance inclined line, the quotes of the company will likely continue to decline within the downward channel to 27.00 dollars per share. Growth is limited by the upper boundary of the descending channel. We expect a further reduction of price in the medium term.

RISK WARNING: Trading of complex financial products, such as Stocks, Futures, Foreign Exchange ("Forex"), Contracts for Difference ("CFDs"), Indices, Options, or other financial derivatives, on "margin" carries a high level of risk, and may not be suitable for all investors. The possibility exists that you could sustain a loss of some or all of your initial investment and, therefore, you should not invest money that you cannot afford to lose. You should be aware of all the risks associated with trading these markets, and seek advice from an independent financial advisor if you have any questions or doubts. Please carefully read our full "Risk Disclosure" and "Risk Disclosures for Financial Instruments & Investment Services". FXFINPRO Capital is the trading name of PFX Financial Professionals Limited, a limited liability company formed under the laws of Cyprus, registered with the Registrar of Companies in Nicosia, Cyprus, under nr. HE 237840 and regulated by the Cyprus Securities and Exchange Commission with license number 193/13.